Citius Oncology, Inc. (CTOR) Financial Ratios
4 years of historical data (2022–2025) · Healthcare · Drug Manufacturers - General
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.48
↓-46% vs avg
5yr avg: 2.74
30Y Low2.2·High3.3
ROE
↓
-54.4%
↑-28% vs avg
5yr avg: -42.4%
30Y Low-59%·High-15%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CTOR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Citius Oncology, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $80M | $149M | $99M | — | — |
| Enterprise Value | $80M | $149M | $103M | — | — |
| P/E Ratio → | -2.67 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 1.48 | 3.32 | 2.16 | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | 787.14 | — | — |
P/E links to full P/E history page with 30-year chart
CTOR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
CTOR Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -54.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -54.4% | -54.4% | -59.0% | -41.1% | -15.0% |
| ROA | -26.7% | -26.7% | -32.0% | -28.1% | -12.7% |
| ROIC | -37.3% | -37.3% | -40.9% | -29.6% | -10.1% |
| ROCE | -45.6% | -45.6% | -52.5% | -38.2% | -13.2% |
CTOR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.08 | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.00 | 0.08 | -0.00 | -0.01 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -107.89 | -107.89 | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($4M)
CTOR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.56x is below 1.0, meaning current liabilities exceed current assets. The quick ratio of 0.11x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 0.37x to 0.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 0.56 | 0.56 | 0.34 | 0.37 | 0.46 |
| Quick Ratio | 0.11 | 0.11 | 0.08 | 0.37 | 0.46 |
| Cash Ratio | 0.08 | 0.08 | 0.00 | 0.00 | 0.05 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
CTOR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Citius Oncology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $73M | $72M | $89M | $90M |
Peer Comparison
Compare CTOR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CTORYou | $80M | -2.7 | — | — | — | — | -54.4% | -37.3% | — |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 ADMA | $2B | 16.8 | 12.3 | 88.4 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 TGTX | $7B | 15.2 | 55.7 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 ACAD | $4B | 9.4 | 25.6 | 35.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRGO | $2B | -1.2 | 7.5 | 11.6 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 JAZZ | $14B | -39.1 | 24.0 | 11.1 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 SUPN | $3B | -75.7 | 52.6 | 64.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 MNKD | $1B | 178.0 | 29.3 | 80.3 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 CLDX | $2B | -8.8 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See CTOR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTOR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTOR vs HALO
Side-by-side business, growth, and profitability comparison vs Halozyme Therapeutics, Inc..
Start ComparisonCTOR — Frequently Asked Questions
Quick answers to the most common questions about buying CTOR stock.
What is Citius Oncology, Inc.'s P/E ratio?
Citius Oncology, Inc.'s current P/E ratio is -2.7x. This places it at the 50th percentile of its historical range.
What is Citius Oncology, Inc.'s ROE?
Citius Oncology, Inc.'s return on equity (ROE) is -54.4%. The historical average is -42.4%.
Is CTOR stock overvalued?
Based on historical data, Citius Oncology, Inc. is trading at a P/E of -2.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.